NHMRC’s puberty blocker advice raises serious questions for children’s health

•

Genspect Australia is deeply concerned by the NHMRC’s puberty blocker advice, released today for public consultation. We urge parents, clinicians and everyone concerned with children’s health to read it and make a submission.

The advice raises serious questions about what now qualifies as a clinical justification for suppressing a child’s puberty. Its conditional recommendation extends to under-18s with gender incongruence with or without distress: a diagnosis of gender dysphoria is not required.

The advice asks clinicians to explore a young person’s “embodiment goals”, how they want their body to look, feel and behave, and its evidence review treats achieving them as a goal of treatment. This risks conflating a desired bodily outcome with demonstrated health benefit. It is a concerning move towards consumer-driven medical care, in which interrupting a child’s natural development is judged a success simply because that is what was asked for. A child’s wish to avoid puberty does not establish that suppressing it offers a favourable balance of lifelong benefits and harms.

The NHMRC’s evidence review found that the evidence that puberty blockers improve gender dysphoria or body image is of very low certainty. Yet the committee judged the benefits “moderate”, largely because the medicines do what they are designed to do: stop pubertal changes. 

In coming weeks, Genspect Australia will examine how the committee reached its recommendation, including its decision to include children without distress, its weighting of physical suppression as a benefit, and its ratings of harms as “trivial” despite substantial gaps in long-term evidence. We will scrutinise the distinction between an absence of evidence of harm and evidence of safety, alongside the handling of bone health, brain development, fertility, sexual function and progression to opposite-sex hormones.

We urge clinicians to assess the advice with a rigorous and critical eye, and everyone concerned to make a submission.

We also welcome your concerns, which will help inform our analysis and Genspect Australia’s submission. Please email contact@genspect.org.au, avoiding identifying details about children or patients. 

The central question is whether NHMRC has established that interrupting normal development improves children’s health or has treated the ability to deliver a young person’s desired physical outcome as sufficient grounds to recommend intervention. 

Read the NHMRC interim advice